An observational study in Acute Myeloid Leukemia, Myeloid Hematological Malignancies and Normal Hematopoietic Stem and Progenitor Cells, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University Hospital, Strasbourg, France · Observational
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML).
This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.
3,035 studies on the registry are indexed under Leukemia, Myeloid, Acute; 746 are open to participants now.
This study's planned enrollment of 50 is below the median of 120 across 323 observational studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →University Hospital, Strasbourg, France is the lead sponsor of 994 studies on the registry; 353 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with confirmed or suspected acute myeloid leukemia, or patients undergoing assessment of hematopoietic stem cells using blood or bone marrow samples, at Strasbourg University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CD180 Expression in Normal and Pathological CD34+ Cells
Percentage of CD34+ cells expressing CD180 above the levels observed in negative control populations (T lymphocytes and neutrophils), and intensity of CD180 expression measured by antibody-based fluorescence intensity.
Time frame: During the 6-month data collection period, from January 21, 2026, to July 21, 2027.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →